No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
USA —Abbott Laboratories, Inc. has concluded its acquisition of Bigfoot Biomedical—an innovative force in intelligent insulin management systems. While financial specifics remain undisclosed, the implications of this union are profound.…
Read More
SOUTH AFRICA — Africa’s leading pharmaceutical company, Aspen Pharmacare, has entered into a groundbreaking agreement with Danish healthcare firm Novo Nordisk to establish South Africa’s first production facility for human…
Read More
UNITED KINGDOM — In a surprising turn of events, the National Institute for Health and Care Excellence (NICE) has issued final draft guidance endorsing Eli Lilly’s Mounjaro (tirzepatide) as a…
Read More
DENMARK — Novo Nordisk, the Danish pharmaceutical giant, has once again seized the spotlight with groundbreaking revelations about its weight loss drug, Wegovy. Following its recent revelation that Wegovy can…
Read More
USA — In a pioneering stride aimed at transforming access to vital diabetes care, Amazon has introduced a remarkable expansion of its online pharmacy offerings, ensuring affordability and comprehensive support…
Read More
UAE – RAK Hospital is rolling out a 3-month-long health challenge, titled RAK Diabetes Challenge 2023, to increase the engagement of residents in the management of diabetes. RAK Hospital, in…
Read More
INDIA – Dr. Reddy’s Laboratories Limited has introduced a new combination product for the treatment of type 2 diabetes in the United States. In a press statement, Dr. Reddy’s Laboratories…
Read More
DENMARK — Novo Nordisk, a pioneering force in diabetes and obesity treatments, is boldly elevating its forecasts following groundbreaking results showcasing the cardiovascular benefits of its drug Wegovy. In a…
Read More
USA — Eli Lilly has experienced a big jump in its yearly predictions, driven by the growing demand for its new diabetes medication, Mounjaro. The hope that it might be…
Read More
DENMARK —Novo Nordisk has released groundbreaking data from a major trial that showcases Wegovy’s remarkable ability to reduce the risk of “adverse cardiovascular events” by a substantial 20%. The company’s…
Read More